Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil in Duchenne Muscular Dystrophy
NCT01865084Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Six Minute Walk Distance at 48 weeks. Started Sep 2013; status: terminated.
02
Drugs
tadalafil
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01865084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01865084.